Publication | Closed Access

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study

ThrombopoiesisThrombosisVenous ThrombosisBlood PlateletAdult PatientsImmunologyClinical TrialsHematologyPlatelet AntagonistImmunotherapyMedicineAnticoagulantHealth Sciences